Kolkata, Sept. 4 -- time prescriptions to continuous patient engagement and measurable health outcomes. Globally, PSPs have grown into a USD 70 billion industry, yet in India they remain a largely untapped opportunity.
Traditionally, PSPs in India were driven primarily by multinational pharmaceutical companies, with Saarathi Healthcare emerging as the pioneering player in this space. Saarathi built its reputation by designing patient-centric programs for chronic disease management and establishing a multinational client base. With the acquisition of a majority stake in Saarathi - and moving toward full ownership - QMS Medical Allied Services Ltd. (QMS MAS) has unlocked greater participation for Indian pharma companies in PSPs, reshaping th...